TABLE 1.

Survey of the literatures using a murine continuous polyethylene particle infusion model: Comparison with the current study in terms of therapeutic intervention and its timing

Authors [ref.]	Publication year	Experimental period	Therapeutic intervention	Delivering method of therapeutic intervention	Timing of therapeutic intervention
Ma T21	2008	4 weeks	NA	NA	NA
Ren PG 24	2011	25 days	NA	NA	NA
Pajarinen J 23	2017	8 weeks	NA	NA	NA
Gibon E 19	2012	5 weeks	Antagonist of the MCP-1 receptor	Daily intraperitoneal injection or daily intravenous injection	Beginning 2 weeks before surgery and 3 weeks after surgery
Gibon E 20	2012	5 weeks	Antagonist of the CCR1 receptor	Daily intraperitoneal injection	Beginning 1 week before surgery and 4 weeks after surgery
Sato T 25	2016	4 weeks	IL-4 7ND-releasiug coating titanium rod	Continuous intramedurally infusion Press-fit into the femur	Day 0–4 weeks after primary surgery Day 0–4 weeks after primary surgery
Nabeshima A 22	2017	4 weeks	7ND-releasiug coating titanium rod	Press-fit into the femur	Day 0–4 weeks after primary surgery
Lin T 13	2017	3 weeks	NF-κB decoy ODN	Continuous intramedurally infusion	Day 0–3 weeks after primary surgery
Lin T 14	2016	4 weeks	NF-κB decoy ODN	Continuous intramedurally infusion	Day 0–4 weeks after primary surgery
The current study		6 weeks	NF-κB decoy ODN	Continuous intramedurally infusion	4–6 weeks after primary surgery

Abbreviations: CCR1, C—C motif receptor 1; IL-4, interleukin-4; MCP-1, monocyte chemoattractant protein-1; NA, not available; NF-κB, nuclear factor kappa B; ODN, oligodeoxynucleotide.